Ribozymes for Treating Hepatitis C
Introduction Hepatitis C virus (HCV) is one of the main causes of liver-associated morbidity and mortality, and is the leading indication for liver transplantation in the western world. It is estimated that HCV infects more than 170 million people worldwide, including 2-4% of Americans. In about 70% of all (usually asymptomatic) acute infections, HCV establishes persistency, which is frequently characterized by chronic liver inflammation and fibrogenesis, and ultimately progresses to cirrhosis, end-stage liver failure and hepatocellular carcinoma. The success rates of treatment of chronic HCV infection are at best 50-60 %, using the most effective currently available regiment in the form of pegylated interferon α, alone or in combination with ribavirin. Therefore, the implementation of alternative safe, effective and specific therapeutics for chronic viral hepatitis is crucial. Technology description Researchers at the University of Washington have developed a method for treating HCV based on the use of ribozymes. Ribozymes are RNA catalytic molecules that cleave other RNA substrates. By flanking the catalytic sequences with sequences complementary to a target site, specific RNAs can be cleaved. This invention comprises a method of inhibiting HCV RNA replication or expression by introducing two or more ribozymes specific for HCV in infected cells. Our scientists hereby provide a potential alternative approach for the treatment of hepatitis C infection. Business Opportunity According to the NIH, hepatitis C causes an estimated 10,000 to 12,000 deaths annually in the United States. The current treatment market for HCV is likely to grow from $3 billion per year to more than $8 billion by 2010. A new and safer therapeutic could increase patient’s outcome and decrease the numerous undesirable side effects associated with the current treatments.Patents:
US 6,107,028
Type of Offer: Licensing
« More Medical Patents